Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00246
|
|||||
| Drug Name |
Ranolazine
|
|||||
| Synonyms |
(-)-Ranolazine; CVT-303; KEG-1295; Latixa; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; RAN D; RS-43285; RS-43285-003; Ran4; Ranexa; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine 2HCl; Ranolazine dihydrochloride
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Chronic angina [ICD11: BA40] | Approved | [1] | |||
| Therapeutic Class |
Analgesics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H33N3O4
|
|||||
| Canonical SMILES |
CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
|
|||||
| InChI |
InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)
|
|||||
| InChIKey |
XKLMZUWKNUAPSZ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 142387-99-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 427.5 | Topological Polar Surface Area | 74.3 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103482101
, 104171232
, 104253386
, 104311416
, 117573069
, 12013498
, 121363701
, 124750209
, 124757504
, 124799345
, 124881338
, 124881339
, 125164308
, 125360240
, 126583887
, 126622101
, 126630205
, 126656915
, 126666839
, 126724363
, 129701807
, 134338152
, 135015431
, 135684171
, 135692283
, 136375567
, 14856376
, 26612929
, 26749060
, 26749061
, 43114706
, 46505145
, 47207361
, 47795040
, 48169373
, 50070803
, 50107515
, 51004683
, 56463697
, 57313861
, 7980486
, 81040983
, 8184974
, 85171832
, 85789241
, 90340842
, 92124680
, 92307911
, 92309225
, 92712119
|
|||||
| ChEBI ID |
CHEBI:87690
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ranolazine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Ranolazine-tacrolimus interaction. Ann Pharmacother. 2010 Nov;44(11):1844-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.